Suppliers and packagers for KLOXXADO

KLOXXADO

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	KLOXXADO	naloxone hydrochloride	SPRAY;NASAL	212045	NDA	Hikma Specialty USA Inc.	59467-679-01	.1 mL in 1 VIAL, SINGLE-DOSE (59467-679-01)	2021-08-03

Kloxxado Drug Supply Chain Analysis

Last updated: February 19, 2026

Kloxxado, a naloxone hydrochloride nasal spray, is manufactured by Hikma Pharmaceuticals. The drug's active pharmaceutical ingredient (API), naloxone hydrochloride, is sourced from a limited number of specialized chemical manufacturers. The finished drug product undergoes formulation, filling, and packaging at Hikma's U.S. facilities, with potential reliance on third-party logistics providers for distribution. Key considerations for ensuring a stable supply chain include API sourcing diversification, robust manufacturing capacity, and proactive inventory management to address fluctuating market demand and regulatory changes.

What is Kloxxado's Active Pharmaceutical Ingredient (API)?

The active pharmaceutical ingredient in Kloxxado is naloxone hydrochloride. Naloxone is a pure opioid antagonist, meaning it binds to opioid receptors and blocks or reverses the effects of opioid overdose. It is the same active ingredient found in Narcan Nasal Spray, another widely used naloxone product.

The chemical formula for naloxone hydrochloride is $\text{C}{19}\text{H}{21}\text{NO}_4 \cdot \text{HCl}$. Its molecular weight is approximately 363.84 g/mol.

Naloxone hydrochloride is synthesized through complex multi-step chemical processes. The manufacturing of naloxone API is a highly specialized field, with a limited number of global suppliers possessing the requisite technical expertise, regulatory compliance (e.g., Good Manufacturing Practices or GMP), and production capacity.

Who are the primary suppliers of naloxone hydrochloride API?

Identifying specific, publicly disclosed suppliers for a proprietary API like naloxone hydrochloride can be challenging due to the confidential nature of pharmaceutical supply chain agreements. However, general information about the naloxone API market indicates that production is concentrated among a few established chemical manufacturers. These suppliers typically operate under stringent quality control and regulatory oversight.

Historically, and as generally understood within the pharmaceutical industry, key API manufacturers that have been involved in the naloxone supply chain include:

• Antares Pharma: While Antares Pharma is the developer and marketer of Kloxxado through its acquisition of Akela Pharma, its role is primarily in the formulation and commercialization. The API manufacturing itself is outsourced.
• Specialized Chemical Manufacturers: The actual synthesis of naloxone hydrochloride is likely performed by contract manufacturing organizations (CMOs) or specialized chemical companies with expertise in producing opiate-derived compounds under strict pharmaceutical standards. These companies often operate globally.

Due to the critical nature of naloxone supply and potential government stockpiling initiatives, specific supplier identities are often not disclosed publicly to maintain supply security and avoid market speculation.

How is Kloxxado manufactured?

Kloxxado is a ready-to-use nasal spray. The manufacturing process involves several key stages:

1. API Sourcing and Quality Control: High-purity naloxone hydrochloride API is procured from a qualified supplier. Rigorous quality control testing is performed to verify identity, purity, potency, and absence of impurities according to pharmacopeial standards (e.g., USP, EP).
2. Formulation: The naloxone hydrochloride API is combined with excipients to create the final drug product solution. Excipients may include:
   • Solvents: Typically purified water.
   • Buffering Agents: To maintain pH stability, crucial for drug efficacy and patient comfort. Examples could include citrate or phosphate buffers.
   • Preservatives: If the formulation is not single-use or if multi-dose packaging is employed, preservatives like benzalkonium chloride might be used to prevent microbial growth.
   • Tonicity Agents: To ensure the solution is isotonic with nasal fluids, reducing irritation. Sodium chloride is a common example.
3. Sterile Filling: The formulated solution is aseptically filled into the nasal spray devices. This process is conducted in controlled cleanroom environments (e.g., ISO Class 5) to prevent microbial contamination.
4. Device Assembly: The filled containers are assembled into the final nasal spray devices. This includes attaching the spray pump mechanism and any protective caps.
5. Packaging: The assembled devices are labeled and packaged into final product cartons, typically including patient information leaflets. Packaging processes must comply with serialization requirements for track-and-trace.
6. Quality Assurance and Release: Throughout the manufacturing process, in-process controls and finished product testing are performed. This includes checks for appearance, pH, assay of naloxone hydrochloride, uniformity of dosage units, sterility, particulate matter, and leachables/extractables from the device components. The finished product is released for distribution only after passing all quality specifications.

Hikma Pharmaceuticals manufactures Kloxxado at its facilities in the United States. Hikma operates multiple manufacturing sites within the U.S. that are equipped to handle sterile product manufacturing and nasal spray device filling. These facilities are regulated by the U.S. Food and Drug Administration (FDA).

What are the key excipients used in Kloxxado?

While the specific proprietary formulation details are not publicly disclosed by Hikma Pharmaceuticals, typical excipients used in naloxone hydrochloride nasal sprays include:

• Purified Water: As the primary solvent.
• Citric Acid/Sodium Citrate: As a buffering agent to maintain pH. The pH of naloxone nasal sprays is generally formulated to be within a range that is compatible with nasal mucosa and ensures drug stability, typically between 4.0 and 6.0.
• Sodium Chloride: To adjust the tonicity of the solution to be isotonic with nasal fluids.
• Benzalkonium Chloride (as preservative): While not all naloxone nasal sprays contain preservatives, some formulations do, especially if designed for multi-use or extended shelf-life after opening. Kloxxado is a single-dose device.

The absence of preservatives in single-dose nasal spray formulations like Kloxxado is a common practice to avoid potential irritation or sensitization and simplify the formulation.

What is the regulatory landscape for Kloxxado and its suppliers?

Kloxxado, as a pharmaceutical product, is subject to extensive regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) and potentially other international health authorities if marketed outside the U.S.

Key regulatory aspects include:

• FDA Approval: Kloxxado received FDA approval on July 16, 2021. Approval is based on demonstrated safety and efficacy, as well as the quality and consistency of the manufacturing process.
• Drug Master Files (DMFs): Suppliers of the naloxone hydrochloride API are required to maintain Drug Master Files (DMFs) with the FDA. A DMF is a submission to the FDA that provides detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows the FDA to review the API's manufacturing without disclosing proprietary information directly to the drug product manufacturer.
• Good Manufacturing Practices (GMP): All facilities involved in the manufacturing of Kloxxado, from API production to finished product assembly, must adhere to current Good Manufacturing Practices (cGMP) as mandated by the FDA. GMP regulations ensure that drugs are consistently produced and controlled according to quality standards. This includes controls over raw materials, production processes, facility maintenance, personnel training, and quality control testing.
• Labeling and Packaging Regulations: Kloxxado's labeling, including prescribing information and patient instructions, must comply with FDA regulations. Serialization and track-and-trace requirements, mandated by the Drug Supply Chain Security Act (DSCSA), also apply to the finished product packaging.
• Emergency Use Authorizations (if applicable): In situations of public health emergencies, regulatory pathways like Emergency Use Authorizations (EUAs) might be relevant for drug products, though Kloxxado's approval is a standard New Drug Application (NDA) pathway.
• DEA Regulations: As naloxone is an opioid antagonist, its API is not a controlled substance. However, any precursor chemicals used in its synthesis may be subject to monitoring by the Drug Enforcement Administration (DEA).

The regulatory burden extends to ensuring the integrity of the entire supply chain, including the reliability and quality of API suppliers. The FDA conducts regular inspections of manufacturing facilities to ensure ongoing compliance with cGMP and other regulations.

What are the challenges in the Kloxxado supply chain?

The supply chain for naloxone products, including Kloxxado, faces several inherent challenges:

• API Sourcing Concentration: The limited number of specialized manufacturers for naloxone hydrochloride API creates a potential bottleneck. Disruptions at any of these facilities, whether due to technical issues, regulatory enforcement, or geopolitical events, can significantly impact global supply.
• Demand Volatility: The demand for naloxone products can fluctuate based on public health initiatives, overdose rates, and government stockpiling efforts. This volatility makes it challenging for manufacturers to accurately forecast production needs, potentially leading to periods of shortage or oversupply.
• Manufacturing Capacity: Scaling up API production or finished product manufacturing to meet sudden surges in demand can be difficult and time-consuming. Building new manufacturing lines or securing additional capacity requires significant investment and regulatory approvals.
• Regulatory Compliance Costs: Maintaining cGMP compliance and navigating the complex regulatory landscape is expensive and requires continuous investment in quality systems, training, and facility upgrades for both API suppliers and the finished drug manufacturer.
• Geopolitical Risks: Reliance on a global supply chain for APIs means exposure to geopolitical instability, trade restrictions, or disruptions in international shipping and logistics.
• Counterfeit Products: The high demand and critical nature of naloxone products can make them targets for counterfeiters. Ensuring the authenticity of both API and finished product throughout the supply chain is paramount.
• Expiration Dates and Inventory Management: Pharmaceuticals have expiration dates. Effective inventory management is crucial to minimize waste due to expired product while ensuring sufficient stock is available to meet demand.

How does competition affect Kloxxado's supply chain?

Kloxxado competes with other naloxone hydrochloride products, most notably Narcan Nasal Spray (manufactured by Emergent BioSolutions). The presence of multiple competitors influences the supply chain in several ways:

• API Supplier Strategy: API suppliers may serve multiple naloxone product manufacturers. Their production capacity allocation decisions can be influenced by the aggregate demand from all their clients. If one competitor faces a supply issue, it can increase demand on the shared API suppliers, potentially affecting the supply available for Kloxxado.
• Manufacturing Capacity Utilization: Hikma's manufacturing capacity for Kloxxado is dedicated to its product. However, the overall availability of contract manufacturing slots for nasal spray devices or sterile filling can be influenced by the production needs of all competing products.
• Pricing and Market Share: Competition influences pricing strategies and market share, which in turn affects the sales volume and revenue generated by Kloxxado. This can impact Hikma's investment decisions regarding manufacturing capacity expansion or API procurement.
• Innovation and Differentiation: While the API is the same, differences in device technology, formulation (e.g., excipients, pH), or packaging can differentiate competing products. These differences can indirectly impact supply chain requirements (e.g., specialized device components).

The competitive landscape necessitates robust supply chain management to ensure Hikma can consistently meet demand for Kloxxado and maintain its market position.

What are the distribution channels for Kloxxado?

Kloxxado is distributed through various channels to ensure accessibility:

• Pharmacies: Prescription and over-the-counter (OTC) availability through retail pharmacies is a primary distribution channel. Patients can obtain Kloxxado with or without a prescription, depending on state laws and FDA classification.
• Hospitals and Healthcare Facilities: Inpatient and outpatient settings within hospitals, clinics, and emergency medical services (EMS) are significant purchasers.
• Government Agencies and Public Health Programs: Federal, state, and local government agencies, as well as public health organizations, procure Kloxxado for distribution through harm reduction programs, community outreach, and emergency preparedness initiatives.
• Wholesalers and Distributors: Pharmaceutical wholesalers, such as Cardinal Health, McKesson, and AmerisourceBergen, play a crucial role in the supply chain. They purchase large quantities of Kloxxado from Hikma and then distribute it to retail pharmacies, hospitals, and other healthcare providers.
• Direct Sales: In some instances, manufacturers may engage in direct sales to large institutional buyers or government entities.

The distribution network requires specialized logistics that can maintain product integrity (e.g., temperature control if necessary, though Kloxxado typically has ambient storage requirements) and comply with regulations for pharmaceutical distribution, including traceability.

What are the storage and handling requirements for Kloxxado?

Kloxxado nasal spray is a pharmaceutical product with specific storage and handling requirements to maintain its efficacy and safety:

• Storage Temperature: Kloxxado should be stored at room temperature, typically between 20°C to 25°C (68°F to 77°F). The FDA-approved labeling may specify acceptable excursion ranges for short periods.
• Protection from Light: While not always explicitly stated as a primary concern for this formulation, pharmaceutical products are generally protected from prolonged exposure to direct light.
• Protection from Freezing: The product should be protected from freezing. Freezing can compromise the integrity of the formulation and the nasal spray device.
• Container Integrity: The nasal spray device should be kept in its original packaging until use to protect it from contamination and damage. The spray tip should not be immersed in water or any other liquid.
• Handling: Users are instructed to administer the spray into one nostril. The device is designed for single-dose administration and should not be reused. After administration, the device should be disposed of properly.

These requirements are critical for maintaining the stability of the naloxone hydrochloride and ensuring the proper functioning of the nasal spray device, thus guaranteeing accurate dosing.

Key Takeaways

• Kloxxado's active pharmaceutical ingredient, naloxone hydrochloride, is produced by a limited number of specialized API manufacturers globally, creating a concentration risk within the supply chain.
• Hikma Pharmaceuticals manufactures the finished Kloxxado nasal spray product in the United States, adhering to strict Good Manufacturing Practices (GMP).
• The formulation involves standard pharmaceutical excipients designed for nasal administration and stability.
• Regulatory oversight by the FDA is extensive, covering API sourcing through DMFs, manufacturing processes, and finished product quality.
• Supply chain challenges include API sourcing concentration, demand volatility, manufacturing capacity limitations, and geopolitical risks.
• Competition from other naloxone products influences API supplier strategies and overall market dynamics.
• Kloxxado is distributed through pharmacies, hospitals, government agencies, and wholesalers, requiring specialized logistics.
• Proper storage at room temperature and protection from freezing are essential for maintaining product integrity.

FAQs

1. What is the primary risk associated with the API sourcing for Kloxxado?

The primary risk is the concentration of naloxone hydrochloride API production among a small number of specialized manufacturers. Any disruption at these facilities could lead to significant supply shortages for Kloxxado and other naloxone products.

2. How does the FDA ensure the quality of naloxone hydrochloride API used in Kloxxado?

The FDA ensures API quality through the review of Drug Master Files (DMFs) submitted by API suppliers and through regular on-site inspections of manufacturing facilities to verify compliance with current Good Manufacturing Practices (cGMP).

3. Can demand for Kloxxado fluctuate significantly, and how does this impact its supply chain?

Yes, demand can fluctuate due to public health crises, changes in overdose rates, and government purchasing patterns. This volatility challenges manufacturers in forecasting production needs, potentially leading to shortages or the need for rapid capacity expansion.

4. What role do pharmaceutical wholesalers play in distributing Kloxxado?

Wholesalers like Cardinal Health, McKesson, and AmerisourceBergen are critical intermediaries. They purchase large volumes of Kloxxado from Hikma and then distribute it to a wide network of retail pharmacies, hospitals, and other healthcare providers, ensuring broad market access.

5. Are there specific temperature requirements for storing Kloxxado to maintain its efficacy?

Kloxxado should be stored at room temperature, generally between 20°C to 25°C (68°F to 77°F), and protected from freezing. Excursions outside this range for short periods may be acceptable as per specific product labeling.

6. How does the regulatory environment for naloxone API suppliers differ from finished drug manufacturers like Hikma?

API suppliers must comply with cGMP for API production and maintain Drug Master Files (DMFs) detailing their manufacturing processes. Finished drug manufacturers like Hikma must also adhere to cGMP for drug product manufacturing, packaging, and labeling, and are directly responsible for the final product's approval and marketing authorization.

7. What are the implications of competition from products like Narcan Nasal Spray on the Kloxxado supply chain?

Competition impacts the utilization of shared API supplier capacity and influences Hikma's production planning and market strategy. It necessitates a robust and efficient supply chain for Kloxxado to remain competitive in terms of availability and reliability.

8. Is Kloxxado available without a prescription in all regions?

Kloxxado is available both by prescription and over-the-counter (OTC) in the United States, depending on state laws and federal regulations. Availability may vary in other countries.

9. What are the main challenges in scaling up production for naloxone nasal spray products?

Scaling up involves challenges in securing sufficient quantities of the specialized naloxone hydrochloride API, increasing sterile filling and device assembly capacity, and obtaining necessary regulatory approvals for expanded manufacturing operations.

10. How is the authenticity of Kloxxado ensured throughout its supply chain?

Authenticity is ensured through stringent supplier qualification, cGMP compliance at all manufacturing stages, secure distribution networks, and potentially serialization and track-and-trace systems mandated by regulations like the DSCSA.

Citations

[1] U.S. Food and Drug Administration. (2021, July 16). FDA approves new naloxone hydrochloride nasal spray for the treatment of opioid overdose. [Press release]. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-naloxone-hydrochloride-nasal-spray-treatment-opioid-overdose [2] Hikma Pharmaceuticals. (n.d.). Kloxxado® (naloxone hydrochloride) nasal spray. Retrieved from https://www.kloxxado.com/ (Note: Specific formulation details are proprietary and not publicly disclosed on the product website). [3] U.S. Pharmacopeia. (n.d.). General Chapters. Retrieved from https://www.uspharmacopeia.org/ (General reference for pharmacopeial standards). [4] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files-dmfs [5] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/current-good-manufacturing-practice-cgmp-regulations [6] Emergent BioSolutions. (n.d.). Narcan® Nasal Spray. Retrieved from https://www.narcan.com/ (For competitive landscape comparison). [7] Drug Supply Chain Security Act (DSCSA). (n.d.). U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa